# BETH ISRAEL DEACONESS MEDICAL CENTER: An Oleoyl Serine Derivative as an Innovative Therapeutic Approach for Osteoporosis

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | BETH ISRAEL DEACONESS MEDICAL CENTER |
| Location | BOSTON, MA |
| Project | An Oleoyl Serine Derivative as an Innovative Therapeutic Approach for Osteoporosis |
| Project number | 1R21AR088602-01 |
| Mechanism | R21 |
| Institute | National Institute of Arthritis and Musculoskeletal and Skin Diseases |
| Award | $430,816 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-18 to 2028-08-31 |
| UEI | C1CPANL3EWK4 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11440446). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.